Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.6.0.2
Consolidated Statements of Operations - USD ($)
12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Revenues:    
Chronic illness monitoring supplies revenues $ 6,327,832 $ 5,994,793
Chronic illness monitoring fee revenues 1,136,314 603,188
Total Chronic illness monitoring revenues 7,464,146 6,597,981
Cost of revenues:    
Chronic illness monitoring supplies cost of revenues 4,876,321 4,669,470
Chronic illness monitoring fee cost of revenues 457,851 527,357
Total Chronic illness monitoring cost of revenues 5,334,172 5,196,827
Gross profit 2,129,974 1,401,154
Operating expenses:    
Selling, general and administrative (including $3,306,047 and $5,762,755, respectively, of stock-based compensation) 8,194,678 10,358,410
Research and development 248,441 106,526
Total operating expenses 8,443,119 10,464,936
Loss from operations (6,313,145) (9,063,782)
Other income (expense):    
Gain on derivatives liability 3,405,035 128,942
Gain on liability settlements 297,067 260,830
Gain on lease termination   91,692
Impairment of goodwill   (825,894)
Other income (expense) (2,618) 14,129
Loss on disposal of property and equipment (2,780) (42,336)
Loss on induced conversion of debt (379,132)  
Interest expense, net (2,963,747) (977,234)
Loss on extinguishment of debt (3,163,240) (927,784)
Total other expense (2,809,415) (2,277,655)
Loss from continuing operations (9,122,560) (11,341,437)
Loss from discontinued operations   (186,232)
Net loss (9,122,560) (11,527,669)
Deemed dividends on redemption of preferred stock (6,484,236)  
Dividends on preferred stock (731,660) (994,983)
Deemed dividends on conversion of accrued dividends to common stock   (301,097)
Net loss attributable to common stockholders $ (16,338,456) $ (12,823,749)
Net loss per common share - basic    
Continuing operations - basic $ (0.17) $ (0.25)
Discontinued operations - basic 0.00 (0.00)
Net loss per common share - basic (0.17) (0.25)
Net loss per common share - diluted    
Continuing operations - diluted (0.19) (0.25)
Discontinued operations - diluted 0.00 (0.00)
Net loss per common share - diluted $ (0.19) $ (0.25)
Weighted average common shares outstanding - basic 96,669,000 51,444,000
Weighted average common shares outstanding - diluted 98,047,503 51,444,000